This is notably the case of navitoclax (an inhibitor of BCL-2, BCL-xL, and BCL-W), which had a high synergy rate with paclitaxel in some subtypes of breast cancer (Jaaks et al., 2022). This evidence concerns the gene BCL2 and breast carcinoma.